Christian-H. Heeger: Does the CHAMPION AF Trial Signal a Potential Paradigm Shift in Stroke Prevention for AF?
Christian-H. Heeger, Head of the Department of Rhythmology at Asklepios Hamburg Altona, Professor of Electrophysiology at University of Lübeck, shared on LinkedIn:
”New evidence in stroke prevention for atrial fibrillation – a potential paradigm shift?
The CHAMPION AF trial is the first large randomized study evaluating the WATCHMAN FLX™ system as a first-line therapy compared to direct oral anticoagulants (DOACs).
Why does this matter?
DOACs remain the standard of care for stroke prevention in non-valvular atrial fibrillation.
However, long-term bleeding risk continues to be a major clinical concern.
Study overview (CHAMPION-AF):
- Randomized controlled trial with ~3,000 patients worldwide
- Comparison: Left atrial appendage closure (LAAC) vs. DOAC therapy
- Multi-year follow-up
Primary endpoints:
- Stroke, cardiovascular death, and systemic embolism (non-inferiority)
- Non-procedural bleeding (superiority)
Study objective:
To demonstrate that a one-time interventional approach can provide a safe and effective long-term alternative to chronic anticoagulation – even in patients without contraindications to oral anticoagulants.
What could this mean for clinical practice?
If confirmed, these findings could significantly expand the role of LAAC—potentially positioning it as an earlier treatment option in stroke prevention strategies for atrial fibrillation.
A highly anticipated study with the potential to reshape treatment pathways.
With Option and Champion patients after or during PVI will also benefit from this strategy!”
Stay updated with Hemostasis Today.
-
Mar 29, 2026, 06:43Joyce Lee-Iannotti: Team Barrow in the Fight Against Stroke and Heart Disease
-
Mar 29, 2026, 06:35Giovanni Merlino: Can We Solve the Stroke Unit Capacity Crisis by Simply Shortening Length of Stay?
-
Mar 29, 2026, 06:28Marek Grygier: CHAMPION-AF Is A Potential Game-Changer in Stroke Prevention
-
Mar 29, 2026, 06:24Ahmad Alenezi: Harrison.ai Secured Its 13th FDA Clearance, And This One Is a Literal Life-Saver
-
Mar 29, 2026, 06:16Kenneth Monaghan: The Domino-Effect in Stroke Recovery Is Powerful
-
Mar 29, 2026, 06:11Christoph B. Olivier: What If We Reduce Cardiovascular Collapse in PE by 60% Without Increasing Bleeding?
-
Mar 29, 2026, 06:06A Call for Targeted Prevention of Postthrombotic Syndrome in Europe – JTH
-
Mar 28, 2026, 19:04Roberta Gualtierotti: High Engagement for Research on Non-Replacement Therapies in Hemophilia
-
Mar 28, 2026, 19:02Marking a Century of Progress in von Willebrand Disease – HFA